Ozempic Injection Schedule: Weekly Dosing & Clinical Timing

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) is administered as a once-weekly subcutaneous injection, making it one of the most convenient GLP-1 receptor agonist schedules available. The standard dosing protocol begins at 0.25 mg weekly and escalates over 16 weeks, with most patients reaching a maintenance dose of 1.0 mg per week.

Understanding your injection schedule is critical for treatment adherence and response optimization. PlexusDx emphasizes precision-wellness planning: knowing when and how to inject, combined with genetic insights into your peptide pathways, can help you and your provider make more informed decisions about dose timing and potential adjustments.

Standard Weekly Injection Protocol and Dose Escalation

Ozempic follows a predictable four-week dose escalation schedule. Weeks 1–4: 0.25 mg weekly; Weeks 5–8: 0.5 mg weekly; Weeks 9–12: 0.75 mg weekly; Weeks 13–16 and beyond: 1.0 mg weekly. This gradual increase helps your body adjust and reduces gastrointestinal side effects.

Some patients may escalate to the 2.0 mg dose for enhanced glycemic control, though this is typically reserved for those with established tolerability. Your provider determines escalation timing based on your clinical response, tolerability, and metabolic goals.

Injection Timing, Frequency, and Maintenance Considerations

The once-weekly dosing schedule offers flexibility in timing. You can inject on the same day each week, though the injection can be taken any time during a 24-hour window around your chosen day without loss of efficacy. This flexibility supports real-world adherence and reduces missed doses.

Dosing Phase	Weekly Dose (mg)	Duration	Primary Goal
Initiation	0.25	Weeks 1–4	Tolerance assessment and GI adjustment
Early escalation	0.5	Weeks 5–8	Dose accumulation and tolerability confirmation
Mid escalation	0.75	Weeks 9–12	Bridging toward therapeutic dose
Maintenance	1.0	Week 13 onward	Sustained glycemic/metabolic control
Enhanced therapy	2.0	Individualized	Increased response for select patients

Genetic and Biomarker Factors Influencing Dose Tolerance

Genetic variation in the GLP1R gene (rs6923761) and GIPR gene (rs1800437) may influence how your body responds to semaglutide dosing and tolerates the escalation schedule. These predispositions can affect the timeline and dose at which you experience optimal response.

Carriers of certain FTO variants (rs9939609) may show different metabolic responses to GLP-1 therapy. Understanding your genetic profile can help your provider anticipate dose timing adjustments and manage side effects proactively, supporting a more personalized escalation strategy.

When to Pause, Skip, or Adjust Your Injection Schedule

If you experience significant gastrointestinal side effects during escalation—nausea, vomiting, or constipation—your provider may recommend extending the time at your current dose before escalating. Delaying escalation by 1–2 weeks is a standard adjustment that does not reduce treatment efficacy.

Missed doses should be taken as soon as you remember, provided it is at least two days before your next scheduled injection. If a dose is missed and your next injection is within 48 hours, skip the missed dose and resume your regular schedule. Your provider should guide any adjustments to your injection timeline.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test analyzes predispositions in key peptide signaling pathways—GLP1R, GIPR, FTO, and MC4R variants—that may help provide context for how your body responds to once-weekly semaglutide dosing. These genetic insights are not deterministic but can support a more informed conversation with your provider about your likely tolerability and response window.

The genetic test reveals predispositions in peptide metabolism and receptor sensitivity, not exact medication response. A patient with specific GLP1R or GIPR variants may show earlier onset of satiety or different gastrointestinal tolerance during dose escalation, helping providers anticipate individual needs and adjust timing accordingly.

Combining your genetic predispositions with clinical biomarkers—fasting glucose, HbA1c trends, and tolerability observations—creates a more complete picture of your personalized treatment plan. This data can support a detailed conversation with your healthcare provider about whether standard once-weekly escalation, extended dose intervals, or alternative formulations may work best for your unique biology.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the goal of the first four weeks on this medication?

Tolerance assessment and gastrointestinal adjustment, according to the article, not weight or glucose targets. The opening phase exists so a provider can see how a patient handles the medication before anything moves. That framing is why the article treats the early period as diagnostic rather than therapeutic, with the clinically meaningful effects expected later in the sequence.

Who might go above the usual maintenance dose?

The article describes a higher level as available for enhanced glycemic control, but says it is typically reserved for patients with established tolerability rather than offered by default. It characterizes that step as individualized and aimed at select patients. The provider determines whether it happens, based on clinical response, tolerability and the patient's metabolic goals.

What happens if side effects show up partway through escalation?

The article says a provider may extend the time spent at the current level before moving up, and describes delaying escalation by one to two weeks as a standard adjustment that does not reduce treatment efficacy. Nausea, vomiting and constipation are the effects it names as prompting that call. The decision sits with the provider, not the patient.

What does a provider weigh when deciding whether to move a patient up?

Clinical response, tolerability and the patient's metabolic goals, according to the article. It pairs those observations with markers such as fasting glucose and HbA1c trends to build a fuller picture over time. The point is that escalation timing is a judgment made against how an individual is actually doing, rather than a calendar that runs on its own.

How do the early phases differ in purpose from the maintenance phase?

The early phases are framed around tolerance assessment, drug accumulation and confirming the patient can handle the medication, essentially bridging toward a therapeutic level. Maintenance is framed differently, around sustained glycemic and metabolic control over the long run. Understanding that shift helps explain why little seems to happen at the start and why patience is built into the schedule.

Related Reading

• Injection Ozempic
• Tirzepatide Dosing Schedule Plexusdx
• Injection Sites For Ozempic
• Ozempic Injection Sites

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.